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Abstract Recent identi¢cation of the prokaryotic genes related
to the catalytic oxygenase domain of mammalian nitric oxide
synthase (NOS) has led to speculations on the origins of the NO
signaling network. NOS activity in eukaryotes relies on the
concerted action of the oxygenase domain with an electron-do-
nating reductase domain that is fused to it. A fused reductase
domain is, however, absent in prokaryotes. Consequently, we
searched bacterial genomes for homologs of the reductase do-
main and identi¢ed candidate genes. On the basis of genomic
sequence and protein structural analysis, we here propose that
sul¢te reductase £avoprotein is a prototype of the mammalian
NOS reductase domain and a complementing interaction part-
ner of the bacterial NOS oxygenase protein.
& 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Nitric oxide is an important signaling molecule that is gen-
erated by the family of nitric oxide synthase (NOS) enzymes
[1]. Three highly homologous mammalian isoforms of NOS
have been identi¢ed, namely: neuronal NOS (nNOS), endo-
thelial NOS (eNOS) and inducible NOS (iNOS). All three are
homodimers in their physiological states. Each of them is
composed of oxygenase and reductase domains [2^7] linked
by an inter-domain peptide that binds calmodulin [5,7]. The
N-terminal oxygenase domain (NOSoxy) contains binding
sites for heme, the substrate L-Arg and the cofactor tetrahy-
drobiopterin (BH4), whereas the C-terminal reductase domain
(NOSred) has binding sites for reduced nicotinamide adenine
dinucleotide phosphate (NADPH), £avin adenine dinucleotide
(FAD) and £avin mononucleotide (FMN) [8^10]. The com-
plex multi-domain structure of di¡erent higher eukaryotic
NOSs is the result of several gene fusions.
There have recently been a number of reports on the iden-
ti¢cation of bacterial homologs of the mammalian NOSoxy
domain [11^13]. These proteins are shorter in their N-terminal
part and therefore lack the zinc ion-binding cysteines, part of
the BH4-binding sites and residues involved in binding the
adjacent subunit in the dimer. The crystal structures of bac-
terial NOS oxygenase domain precursor (bNOSoxy) proteins
from Staphylococcus aureus, Bacillus subtilis and Deinococcus
radiodurans [14^16] reveal a similar overall fold to mammalian
NOS and, despite the missing N-terminal part, the proteins
form dimers. bNOSoxy proteins from D. radiodurans, B. sub-
tilis, Nocardia, and S. aureus have been shown to have NOS
activity, as evidenced by detection of NO/nitrate and citrulline
production in the presence of L-Arg and BH4 [16^19].
BH4 is commonly known to be absent in prokaryotes
[16,20]. However, another reduced pteridine produced by bac-
teria, tetrahydrofolate, could support NO production from
B. subtilis and D. radiodurans [16,17]. Interestingly, it has
been proposed that NO generated by pathogenic organisms
could have a critical role during infections [19].
On the other hand, NOS activity in eukaryotes relies on the
electron-donating reductase domain (NOSred). The electron
transfer pathway is from NADPH through FAD and FMN
to the heme domain. Provocatively, it has been veri¢ed that
bNOSoxy are capable of accepting electrons from a mamma-
lian NOS reductase domain under in vitro conditions [16,17].
This observation suggests that bacterial genomes may also
hold a homolog of the NOS reductase domain.
Using a combination of bioinformatics tools including ge-
nomic search and comparison as well as protein structural
analysis, we point to the sul¢te reductase £avoprotein (SiR-
FP) as being a prototype of a mammalian NOS reductase
domain and a complementing interaction partner of the bac-
terial NOS oxygenase protein.
2. Materials and methods
To search and compile potential bacterial NOS homologs, the two
well known large databases located at www.tigr.org and www.ncbi.
nih.gov were queried. The SMART tool (smart.embl-heidelberg.de)
[21,22] was applied to determine borders of functional domains in
sequences that were then aligned using ClustalX v.1.81 [23].
Superimpositions of the structures of a mammalian nNOS reduc-
tase domain (rat, pdb: 1F20) and a bacterial SiR (Escherichia coli,
pdb: 1DDI) were performed using ProSup v.3.0 [24]. The S. aureus
SiR FMN domain was modeled using the Swiss-Model modeling
server [25] with the Bacillus megaterium FMN domain (pdb: 1BVY)
as a template. Superimposition-based docking of the modeled bacte-
rial FMN domain to bNOSoxy was done manually with Swiss PDB
viewer v.3.7 [26] without energetic re¢nement. The pdb coordinates of
the di¡erent models are available on request from the authors.
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3. Results and discussion
The mammalian NOSred domain possesses the same pro-
tein architecture as a family of proteins including SiR, P450
oxidoreductase and cytochrome P450 BM-3, which all contain
FMN-, FAD- and NADPH-binding sites. They are all mem-
bers of the same cluster of orthologous groups (COG),
COG0369 (www.ncbi.nlm.nih.gov/COG [27], www.bork.embl.
de/STRING [28]).
Given the domain composition of the eukaryotic NOS en-
zyme, we looked for a prokaryotic reductase domain that, if
present, could complement the bNOSoxy protein in bacteria
in full functionality.
3.1. Identi¢cation of bNOSoxy in bacterial genomes
First, bacterial genomic databases (containing more than
250 genomes) were queried with sequences of oxygenase do-
mains of each of the three mammalian NOS isoforms (neuro-
nal, endothelial, inducible). From this extensive search, we
identi¢ed only eight bacterial species bearing bNOSoxy. Seven
of these are members of the Firmicutes family: (1) B. subtilis
{168}, O34453; (2) Bacillus halodurans {C-125}, NP_241689;
(3) Oceanobacillus iheyensis {HTE831}, NP_693612; (4) S. au-
reus {COL, N315, Mu50, MW2}, SA1976, NP_374522,
BAB58076, BAB95720; (5) Staphylococcus epidermidis
{ATCC 12228}, AAo05197; (6) Bacillus anthracis {A2012},
NP_653913; (7) Bacillus cereus {ATCC 14579}, NP_835105,
and one of them is a member of the Deinococcus-Thermus
family: (8) D. radiodurans {R1}, Q9RR97.
We repeated the search for bNOSoxy using the identi¢ed
genes as query sequences but this did not yield any additional
homologous sequences.
3.2. Co-existence of bNOSoxy and homologs of the mammalian
reductase domain in bacteria
In the next step, we investigated which potential comple-
menting reductase domain, if any, could be identi¢ed in these
eight bacterial genomes. No protein or domain has been as-
signed as a NOSred homolog in these bacteria before. We
used sequences of the reductase domains from each of the
three mammalian NOS isoforms to conduct BLAST searches
against the bNOSoxy-containing bacterial genomes. Genomes
1^5 from the Firmicutes family revealed the existence of a
highly homologous SiR-FP.
Taking into account the domain architecture and structure,
we found only one more protein displaying a domain organi-
zation similar to eukaryotic NOSred: a BM-3-like bifunction-
al cytochrome. It is present in the following three out of the
eight bNOSoxy-containing bacterial genomes: B. subtilis
{168} (CAB12544), B. anthracis {A2112} (NP_657092) and
B. cereus {ATCC 14579} (NP_832952). Table 1 summarizes
the occurrence of BM-3 and SiR in bacterial genomes bearing
the bNOSoxy.
The alignment in Fig. 1 shows the high conservation of
residues between NOSred, SiR-FP and the reductase domain
of the BM-3-like cytochrome P450, and allows detailed com-
parison of the similarity in the domain architecture.
The BM-3-like P450 and the SiR-FP are the only proteins
that provide the full functionality of the NOSred domain ^
that is, the capability of catalyzing electron transfer from the
NADPH-binding domain via FAD to the FMN domain.
However, structural analysis (data not presented) shows that
the reductase domain of BM-3 is already linked with its oxy
domain by a peptide and therefore cannot serve as a £exible
interaction partner for bNOSoxy.
3.3. Dual functionality of SiR-FP
The SiR-FP identi¢ed is known to be an electron-donating
partner for SiR hemoprotein (SiR-HP). Both interact strongly
in vivo in many bacterial species, catalyzing the transfer of
electrons from NADPH to sul¢te to produce sul¢de. Interest-
ingly, although both SiR-FP and SiR-HP are normally part of
one operon in bacterial genomes, the S. aureus {COL, N315,
Mu50, MW2} genome (#4) lacks SiR-HP, while it has a SiR-
FP. This fact argues for SiR-FP also being an interaction
partner for other proteins. In Section 3.4, we will examine
structural arguments that SiR-FP is capable of donating elec-
trons not only to SiR-HP but also to bNOSoxy protein.
3.4. SiR docked to bNOS can act as an electron-donating
system
Whereas the primary structure conservation between
NOSred and SiR-FP is suggestive, the question arises as to
whether bNOSoxy has a functional docking site capable of
interfacing with the reductase domain. This is particularly
pertinent as two recent papers describe electron-transfer-active
chimeras comprised of bNOSoxy proteins (D. radiodurans and
B. subtilis) and mammalian nNOS reductase domains [16,17].
This is also in agreement with another recent study report-
ing from puri¢cation of heterodimeric NOS from S. aureus
that the complex contains a reductase domain as a subunit
[29].
Interestingly, our structural alignment depicts a high level
of homology between the FAD^NADPH domains of mam-
malian nNOS (rat) and bacterial SiR (E. coli) (Fig. 2).
The only reported crystal structure of a complex between
the heme domain and the FMN domain is that of the BM-3
cytochrome P450 from B. megaterium [30]. It reveals ‘cross-
Table 1
Occurrence of NOSred homologs in eight bacterial genomes (see
text for details)
NOSred homolog 1 2 3 4 5 6 7 8
SiR-FP + + + + + 3 3 3
BM-3 + 3 3 3 3 + + 3
6
Fig. 1. Sequence alignment of reductase domains of SiR (SULFRED_OI: O. iheyensis {HTE831}, BAC13609; SULFRED_BH: B. halodurans
{C-125}, NP_241475; SULFRED_BS: B. subtilis {168}, CAB15349; SULFRED_SA: S. aureus {MW2}, BAB96405; SULFRED_SE: S. epider-
midis {ATCC 12228}, NP_765735; SULFRED_EC: E. coli {B} P38038), NOS (NOS_MS: Manduca sexta, AAC61262; NOS_AS: Anopheles
stephensi, O61608; NOS_DM: Drosophila melanogaster, NP_523541; eNOS_B: endothelial NOS, bovine, P29473; nNOS_M: neuronal NOS,
Mus musculus, Q9Z0J4; iNOS_M: M. musculus, AAM11887; nNOS_LS: neuronal NOS, Lymnaea stagnalis, O61309), cytochrome BM-3 (P450/
NADPH_BM: B. megaterium, P14779; P450/NADPH_BS: B. subtilis {168}, CAB12544; P450/NADPH_BA: B. anthracis A2012, NP_657092).
Three functional domains, FMN, FAD, NADPH, that are conserved among species are outlined just above the sequences in the alignment.
Low-homology/non-homologous regions were cut out of the alignment and designated by -//-.
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talk’ at the docking interface involving methyl groups of the
FMN domain positioned toward the heme-binding loop. Tak-
ing into account the homology in the FMN domains of BM-3
P450 and SiRs (Fig. 1), and a similarity in the structures of
the BM-3 and bNOSoxy heme-binding loops, one might ex-
pect a similar interaction between bNOSoxy and SiR.
We therefore used the P450 BM-3 structure as a template to
create a model of S. aureus bNOSoxy protein complexed with
the FMN domain of the S. aureus SiR. The heme-binding
loops as well as the heme groups were superimposed for this
purpose. In the resulting model, the FMN domain ¢ts well in
the cleft present in the vicinity of the NOSoxy N-terminal
region (Fig. 3). The model therefore constitutes a possible
con¢guration of a docking mode for bacterial NOSoxy that
would not be possible for eukaryotic NOSs with an extended
N-terminal part. The mammalian NOSoxy domains of the
three known isoforms di¡er from each other in the peptide
length involved in the dimer interface N-terminal extension.
Of these, only nNOS is expressed as a catalytically active N-
terminally truncated form (nNOSQ) resembling that of bNOS-
oxy. It has just recently been shown that an N-terminal dele-
tion mutant v349nNOS (similar to nNOSQ and bNOSoxy)
exhibits a slower heme reduction, possibly due to a changed
FMN domain orientation [31]. Therefore, it is tempting to
speculate that the docking site for the FMN domain may be
di¡erent between bacteria and full-length eukaryotic NOSs.
This would also be consistent with the recent study of chime-
ric proteins by Roman et al. [32] that suggests di¡erences in
the alignment of the nNOS and cytochrome P450 reductase
FMN domains with the NOSoxy domain.
The green arrow in Fig. 3 marks the C-terminal part of the
FMN domain (residues colored in yellow), which would be
connected with the FAD domain. Consistent with this, it is
surface-exposed in the model. We do not propose a single
relative orientation of the FMN and FAD/NADPH subunits,
due to a fact that the SiR-FP £avodoxin domain is known to
sample a wide range of con¢gurations for optimal electron
transfer [33]. SiR-FP is octameric in solution [34], and there-
fore it has been suggested that the FMN domain occupies a
central position for the electron transfer to occur [33]. Never-
theless, since the docked structure obtained for bNOSoxy^
(SiR-FP)^FMN shows a similar distance between the heme-
binding loop and the FMN domain to that of BM-3oxy-
FMN, we conclude that this particular domain arrangement
allows for e⁄cient electron transfer.
3.5. Observed diversity
We observe diversity among bacterial genomes bearing
bNOSoxy manifested in the lack of SiR-FP in three out of
eight of them. Among those genomes, D. radiodurans contains
no reductase domain homolog. The enzymatic function of
bNOSoxy could vary among bacterial species depending on
environmental pressures. Similarly, the lack of SiR-HP in the
S. aureus genome (see above) supports SiR-FP being involved
in interactions with other partners (such as bNOSoxy). This
has also been demonstrated on a functional level using an
N-terminally truncated form of SiR-FP, which was capable
of transferring electrons to a cytochrome P450 (12^15 times
less e⁄ciently than bovine P450 reductase) [35].
3.6. Triggering evolution: from the fusion event to a complex
signaling system
The architecture of mammalian NOS, hypothesized here to
result from fusion between bNOSoxy and SiR-FP (Fig. 4),
Fig. 2. Superimposition of the FAD/NADPH-binding domain of
SiR (E. coli, pdb: 1DDI) and the FAD/NADPH-binding domain of
nNOS (rat, pdb: 1F20), colored in blue and gray respectively. Root
mean square (RMS) value calculated with Prosup v.3.0 (see Sec-
tion 2) is 1.71 AX .
Fig. 3. Docking of the modeled S. aureus FMN domain to the bNOSoxy protein (S. aureus, pdb: 1MJT) obtained by superimposition on the
complex of the heme- and FMN-binding domains of cytochrome P450 (BM-3) (B. megaterium, pdb: 1BVY). Dark blue colored ribbons desig-
nate the FMN domain. Left: Hemes are in red, the FMN in green, residues in the heme-binding loop used for superimposition in cyan and
C-terminal residues in yellow. Green arrow as described in the text marks the C-terminal residues. Right: Molecular surface mapped onto the
bNOSoxy and the FMN domains.
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could only originate from a bacterial genome that contains
both proteins (such as the ¢ve we identify here).
The result of an envisioned fusion event leading to two
domains being expressed in one amino acid chain should al-
low for e⁄cient NO catalysis in eukaryotes. A similar type of
optimization of enzyme turnover e⁄ciency, based on electron
£ow between two peptide-connected domains, is observed in
the bacterial bidomain cytochrome BM-3 system.
The presence of BM-3/NADPH in the three bacterial ge-
nomes bearing bNOSoxy suggests (Table 1) that the oxygen-
ase domain of the BM-3-like cytochrome fused with its com-
plementary reductase domain before bNOSoxy did.
We cannot exclude a scenario according to which bNOSoxy
does not result in NO-producing function in bacteria. The
NO/nitrate-producing actions of a bNOSoxy enzyme would
depend on the availability of an electron-donating partner.
The lack of an already fused bNOSoxy^bNOSred system in
bacteria (con¢rmed by an extensive sequence search in over
250 available bacterial genomes) may imply that the introduc-
tion of an e⁄cient NO signaling system relying on intensive
interactions with an electron-donating reductase domain was
only advantageous in the eukaryotic line.
In summary, bacterial SiR-FP, being a close structural
homolog of mammalian NOSred (Fig. 2) and a plausible
electron-donating partner (Fig. 3), ful¢lls all the necessary
conditions, including detailed structural features, genome co-
occurrence and domain architecture, to be a functional com-
plementing partner of the bacterial NOSoxy protein and at
the same time emerges as the best candidate identi¢ed for a
fusion partner giving rise to eukaryotic NOS.
3.7. Outlook
This hypothesis paper should trigger experimental examina-
tion of the possibility of electron £ow between the FMN
domain of SiR-FP and bNOSoxy.
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